NVS

FDA Rejects Novartis Heart Failure Drug Serelaxin

NVS stock fell Friday morning after the FDA rejected Novartis' bid for approval for the acute heart failure drug serelaxin. More 

Hottest Healthcare Stocks Now – HMSY CYH VRTX CELG

Healthcare stocks finished flat today on Wall Street. NASDAQ:HMSY, NYSE:CYH, NASDAQ:VRTX, NASDAQ:CELG, NASDAQ:AMGN, NYSE:MRK, NYSE:HAE, NYSE:NVS, NASDAQ:GILD, NYSE:ABT, NASDAQ:PCRX, NYSE:MSA, NYSE:PBYI, NASDAQ:ALNY, NASDAQ:PODD, NASDAQ:THOR, NYSE:WCG, NYSE:OMI, NYSE:STE, NYSE:TARO More 

Biggest Movers in Healthcare Stocks Now – FURX AZN TECH PFE

Healthcare stocks advanced broadly on Wall Street so far on Monday, with the sector seeing an overall increase of 0.5%. NASDAQ:FURX, NYSE:AZN, NASDAQ:TECH, NYSE:PFE, NASDAQ:ALNY, NASDAQ:SHPG, NASDAQ:GILD, NYSE:SNY, NASDAQ:SRPT, NYSE:NVS, NYSE:HAE, NASDAQ:MYL, NASDAQ:PRXL, NASDAQ:PCRX, NASDAQ:ARIA, NASDAQ:ACAD, NASDAQ:CLDX, NYSE:LH, NYSE:LCI, NASDAQ:AEGR More 

NVS: Novartis Announces Multi-Billion-Dollar Deals With GSK, LLY

Pharmaceutical company Novartis (NVS) has announced a business model change regarding multibillion-dollar deals with GlaxoSmithKline and Eli Lilly & Co. More 

Biggest Movers in Healthcare Stocks Now – ISRG NKTR PCRX QCOR

Healthcare stocks advanced 0.8% on Wall Street on Tuesday morning. NASDAQ:ISRG, NASDAQ:NKTR, NASDAQ:PCRX, NASDAQ:QCOR, NASDAQ:AUXL, NASDAQ:ALXN, NASDAQ:CELG, NASDAQ:HZNP, NASDAQ:THRX, NASDAQ:REGN, NASDAQ:MDCO, NYSE:TEVA, NYSE:SNY, NYSE:NVO, NYSE:COV, NYSE:GSK, NYSE:NVS, NASDAQ:ENDP, NASDAQ:SGMO, NASDAQ:NVDQ More 

Biggest Movers in Healthcare Stocks Now – PCRX HALO TEVA NVS

Healthcare stocks advanced broadly 0.8% on Wall Street so far on Monday. NASDAQ:PCRX, NASDAQ:HALO, NYSE:TEVA, NYSE:NVS, NASDAQ:ALNY, NYSE:WX, NASDAQ:BIIB, NASDAQ:NPSP, NASDAQ:ISIS, NASDAQ:INCY, NASDAQ:MNKD, NYSE:PBYI, NASDAQ:CLVS, NASDAQ:PODD, NASDAQ:ARIA, NASDAQ:MYL, NYSE:RDY, NASDAQ:CLDX, NYSE:SNN, NASDAQ:XLRN More 

The Revised Coffee-Can Portfolio: What’s in Store for 2014?

The revised coffee-can portfolio achieved mixed results in 2013. The same is true since its inception. Here's a look at the portfolio's chances in 2014. More